ICU · Oncology
Tumour lysis syndrome
Also known as Tumour lysis syndrome (TLS) · Hyperuricaemia · Rasburicase · Acute tumour lysis syndrome (ATLS) · Cairo-Bishop classification · Urate nephropathy · Tumor lysis syndrome
Tumour lysis syndrome (TLS) is a metabolic oncological emergency from rapid malignant cell lysis releasing intracellular contents: HYPERKALAEMIA (intracellular K+ dumped — most dangerous, causes fatal arrhythmia), HYPERPHOSPHATAEMIA (phosphate-rich malignant cells release their intracellular phosphate load), HYPOCALCAEMIA (secondary — Ca2+ precipitates with phosphate as calcium-phosphate crystals), and HYPERURICAEMIA (nucleic acid breakdown → purines → xanthine → uric acid via xanthine oxidase). Uric acid and calcium-phosphate precipitate in renal tubules → acute kidney injury (AKI), which then reduces K+ and phosphate excretion → a self-amplifying vicious cycle. Onset typically within days of starting chemotherapy/radiotherapy/corticosteroids/targeted therapy for high-turnover tumours (ALL, Burkitt lymphoma, lymphoblastic lymphoma, high-grade NHL, AML); spontaneous TLS can precede therapy in bulky disease. Cairo-Bishop definition: laboratory TLS (≥2 abnormal values — urate ≥8 mg/dL/476 µmol/L, K+ ≥6.0 mmol/L, phosphate ≥4.5 mg/dL adult/≥6.5 child, Ca2+ ≤7.0 mg/dL/1.75 mmol/L, or 25% change within 3 days before to 7 days after therapy) vs clinical TLS (LTLS PLUS AKI, arrhythmia/sudden death, or seizure). Prevention is the cornerstone: aggressive IV hydration 2500-3000 mL/m2/day (goal urine output ≥2 mL/kg/h) + rasburicase 0.20 mg/kg/day IV for HIGH risk (recombinant urate oxidase — converts EXISTING uric acid → soluble allantoin; CONTRAINDICATED in G6PD deficiency) or allopurinol 300 mg/day for INTERMEDIATE risk (xanthine oxidase inhibitor — prevents NEW uric acid only). Treatment: aggressive hydration, rasburicase, treat hyperkalaemia per protocol (calcium gluconate → insulin-dextrose → salbutamol → binders → RRT), do NOT routinely treat asymptomatic hypocalcaemia, RRT for refractory electrolyte disturbance or AKI. Do NOT alkalinise urine (worsens calcium-phosphate precipitation).
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Target exams
Red flags
- Hyperkalaemia is the MOST dangerous feature — can cause fatal arrhythmia. Treat per protocol: IV calcium gluconate for ECG changes (membrane stabilisation, does NOT lower K+), then insulin 10 units with 25 g glucose IV and nebulised salbutamol 10-20 mg (shift K+ intracellularly), potassium binders, and RRT if refractory — haemodialysis and haemofiltration remove potassium effectively.
- Rasburicase is CONTRAINDICATED in G6PD deficiency — it generates hydrogen peroxide that oxidises G6PD-deficient RBCs, causing haemolytic anaemia and methaemoglobinaemia. Screen BEFORE administering rasburicase, particularly patients of African or Mediterranean ancestry (about 12% of African-Americans are G6PD deficient); allopurinol is the alternative when rasburicase is contraindicated.
- Do NOT routinely treat asymptomatic hypocalcaemia. Hypocalcaemia in TLS is SECONDARY to hyperphosphataemia (Ca-P precipitation). Giving calcium worsens calcium-phosphate deposition in renal tubules (nephrocalcinosis) and worsens AKI. Treat ONLY if symptomatic (tetany, seizures, Chvostek/Trousseau, prolonged QT with arrhythmia).
- Do NOT alkalinise the urine. Sodium bicarbonate increases urinary pH → promotes calcium-phosphate precipitation in renal tubules, worsening AKI. Alkalinisation is not recommended in modern practice and should be avoided especially when rasburicase is available; if used at all, stop it once hyperphosphataemia develops.
- TLS declares within days of starting cytotoxic therapy (the laboratory-TLS window runs from 3 days before to 7 days after starting therapy) — continuous cardiac monitoring and 4-6-hourly electrolytes for high-risk patients. Spontaneous TLS (before therapy) can occur in high-burden disease — hyperuricaemia/AKI may already be present at diagnosis.
- Uric acid blood samples after rasburicase MUST be transported ON ICE and processed immediately — rasburicase continues to degrade uric acid to allantoin in the collection tube at room temperature, giving spuriously LOW uric acid levels (false reassurance).
Meet the patient
A constructed ward vignette in the classic pattern — TLS arises shortly after effective treatment starts in a patient with a large cancer mass, most often a non-Hodgkin lymphoma or acute leukaemia, and hyperkalaemia is the component that threatens the heart. [1]
A 34-year-old man with newly diagnosed Burkitt lymphoma and a large abdominal mass is on the haematology ward, 18 hours into his first cycle of chemotherapy. He complains of weakness and palpitations. The ECG shows a widened QRS trending to a sine wave. The VBG comes back potassium 7.8 mmol/L. [1]
The question that decides his next ten minutes is the question that decides every TLS: is the potassium threatening the myocardium right now? The ECG answers at once, and here it is yes — so you membrane-stabilise first and earn the rest of your questions afterwards. [1]
References14ShowHide
- [1]Howard SC, Avagyan A, Workeneh B, et al. Tumour lysis syndrome Nat Rev Dis Primers, 2024.PMID 39174582
- [2]Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification Br J Haematol, 2004.PMID 15384972
- [3]Cairo MS, Coiffier B, Reiter A, Younes A; TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus Br J Haematol, 2010.PMID 20331465
- [4]Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review J Clin Oncol, 2008.PMID 18509186
- [5]Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study J Clin Oncol, 2010.PMID 20713865
- [6]Howard SC, Jones DP, Pui CH. The tumor lysis syndrome N Engl J Med, 2011.PMID 21561350
- [7]Jones GL, Will A, Jackson GH, Webb NJ, Rule S; British Committee for Standards in Haematology. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology Br J Haematol, 2015.PMID 25876990
- [8]Dean L, Kane M. Rasburicase Therapy and G6PD and CYB5R Genotype Medical Genetics Summaries (NCBI Bookshelf), 2012.PMID 32997466
- [9]Geldermann N, Dzimiera J, Fischer H, et al. Acute hyperkalaemia in emergency care: evidence-based approaches Emerg Med J, 2026.PMID 41506858
- [10]Kijprasert W, Tarudeeyathaworn N, Loketkrawee C, et al. Predicting hypoglycemia after treatment of hyperkalemia with insulin and glucose BMC Emerg Med, 2022.PMID 36371171
- [11]Moussavi K, Fitter S, Gabrielson SW, et al. Management of Hyperkalemia With Insulin and Glucose: Pearls for the Emergency Clinician J Emerg Med, 2019.PMID 31084947
- [12]Allon M, Dunlay R, Copkney C. Nebulized albuterol for acute hyperkalemia in patients on hemodialysis Ann Intern Med, 1989.PMID 2919849
- [13]Vachhani P, Baron J, Freyer CW, et al. A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia Leuk Res, 2021.PMID 33957371
- [14]Meraz-Munoz A, Langote A, D Jhaveri K, et al. Acute Kidney Injury in the Patient with Cancer Diagnostics (Basel), 2021.PMID 33805529